{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:02:50Z","timestamp":1794646970392,"version":"4.9.1"},"reference-count":156,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jaut.2024.103329","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T05:38:19Z","timestamp":1730785099000},"page":"103329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["The emerging role of BLyS\/APRIL in autoimmune diseases: Biological characteristics, functions, and therapeutic potential"],"prefix":"10.1016","volume":"149","author":[{"given":"Shi-Zhi","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan-Yuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Xun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Jia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He-Qin","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2024.103329_bib1","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.autrev.2012.02.001","article-title":"Updated assessment of the prevalence, spectrum and case definition of autoimmune disease","volume":"11","author":"Hayter","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2024.103329_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103155","article-title":"Emerging role of the cGAS-STING signaling pathway in autoimmune diseases: biologic function, mechanisms and clinical prospection","volume":"21","author":"Hu","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2024.103329_bib3","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"Takeuchi","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jaut.2024.103329_bib4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3390\/genes10050405","article-title":"The influence of diet and obesity on gene expression in SLE","volume":"10","author":"La Cava","year":"2019","journal-title":"Genes"},{"key":"10.1016\/j.jaut.2024.103329_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/ar1222","article-title":"The current status of targeting BAFF\/BLyS for autoimmune diseases","volume":"6","author":"Ramanujam","year":"2004","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2024.103329_bib6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1191\/0961203304lu1019oa","article-title":"A therapeutic role for BLyS antagonists","volume":"13","author":"Stohl","year":"2004","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2024.103329_bib7","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1191\/0961203303lu2137oa","article-title":"BLyS antagonists and peptide tolerance induction","volume":"14","author":"Merrill","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2024.103329_bib8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000082108","article-title":"BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists","volume":"8","author":"Stohl","year":"2005","journal-title":"Curr. Dir. Autoimmun."},{"key":"10.1016\/j.jaut.2024.103329_bib9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35010115","article-title":"TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease","volume":"404","author":"Gross","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2024.103329_bib10","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1002\/art.11354","article-title":"B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations","volume":"48","author":"Stohl","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2024.103329_bib11","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/ard.2004.022491","article-title":"Raised serum APRIL levels in patients with systemic lupus erythematosus","volume":"64","author":"Koyama","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103329_bib12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/ar755","article-title":"SLE--systemic lupus erythematosus: a BLySful, yet BAFFling, disorder","volume":"5","author":"Stohl","year":"2003","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2024.103329_bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000066854","article-title":"BLyS and B cell autoimmunity","volume":"6","author":"Zhou","year":"2003","journal-title":"Curr. Dir. Autoimmun."},{"key":"10.1016\/j.jaut.2024.103329_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2008.08.027","article-title":"BAFF-targeting therapy, a promising strategy for treating autoimmune diseases","volume":"597","author":"Sun","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jaut.2024.103329_bib15","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/247426","article-title":"Effect of TACI signaling on humoral immunity and autoimmune diseases","volume":"2015","author":"Zhang","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jaut.2024.103329_bib16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.smim.2006.04.004","article-title":"BAFF, APRIL and human B cell disorders","volume":"18","author":"Tangye","year":"2006","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib17","doi-asserted-by":"crossref","first-page":"18878","DOI":"10.1074\/jbc.M513315200","article-title":"Nuclear localization in the biology of the CD40 receptor in normal and neoplastic human B lymphocytes","volume":"281","author":"Lin-Lee","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jaut.2024.103329_bib18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1359-6101(03)00023-6","article-title":"The TNF family members BAFF and APRIL: the growing complexity","volume":"14","author":"Mackay","year":"2003","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.jaut.2024.103329_bib19","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.173.2.807","article-title":"B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells","volume":"173","author":"Ng","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd1982","article-title":"An APRIL to remember: novel TNF ligands as therapeutic targets","volume":"5","author":"Dillon","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jaut.2024.103329_bib21","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1084\/jem.20042309","article-title":"Identification of proteoglycans as the APRIL-specific binding partners","volume":"201","author":"Ingold","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2024.103329_bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00005-020-00597-z","article-title":"A proliferation-inducing ligand regulation in polymorphonuclear neutrophils by panax ginseng","volume":"68","author":"Ratajczak-Wrona","year":"2020","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.jaut.2024.103329_bib23","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1172\/JCI0215034","article-title":"APRIL modulates B and T cell immunity","volume":"109","author":"Stein","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2024.103329_bib24","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.4049\/jimmunol.169.8.4314","article-title":"BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases","volume":"169","author":"Roschke","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib25","first-page":"2887","article-title":"APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa","volume":"118","author":"Huard","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2024.103329_bib26","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2007-09-110858","article-title":"APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells","volume":"111","author":"Belnoue","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2024.103329_bib27","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2007.04.014","article-title":"Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL","volume":"26","author":"He","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2024.103329_bib28","doi-asserted-by":"crossref","first-page":"6736","DOI":"10.4049\/jimmunol.176.11.6736","article-title":"APRIL and BAFF promote increased viability of replicating human B2 cells via mechanism involving cyclooxygenase 2","volume":"176","author":"Mongini","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib29","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jaci.2007.06.012","article-title":"Transmembrane activator and calcium modulator and cyclophilin ligand interactor enhances CD40-driven plasma cell differentiation","volume":"120","author":"Castigli","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib30","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1182\/blood-2014-05-575845","article-title":"Differential induction of plasma cells by isoforms of human TACI","volume":"125","author":"Garcia-Carmona","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2024.103329_bib31","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1084\/jem.20160832","article-title":"Plasma cell output from germinal centers is regulated by signals from Tfh and stromal cells","volume":"215","author":"Zhang","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2024.103329_bib32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1084\/jem.192.1.129","article-title":"BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population","volume":"192","author":"Thompson","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2024.103329_bib33","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1126\/science.1061965","article-title":"BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF","volume":"293","author":"Thompson","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jaut.2024.103329_bib34","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0960-9822(01)00481-X","article-title":"Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency","volume":"11","author":"Yan","year":"2001","journal-title":"Curr. Biol."},{"key":"10.1016\/j.jaut.2024.103329_bib35","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1172\/JCI38010","article-title":"The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus","volume":"119","author":"Cancro","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2024.103329_bib36","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/09612033221086123","article-title":"The relationship between serum A proliferation-inducing ligand and B-cell activating factor levels with disease activity and organ involvement in systemic lupus erythematosus","volume":"31","author":"Sari","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2024.103329_bib37","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/ard.2007.079954","article-title":"B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders","volume":"67","author":"La","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103329_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2019.103925","article-title":"A proliferation-inducing ligand (APRIL) induced hyper-production of IgA from tonsillar mononuclear cells in patients with IgA nephropathy","volume":"341","author":"Takahara","year":"2019","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib39","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jneuroim.2005.06.024","article-title":"Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis","volume":"167","author":"Thangarajh","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jaut.2024.103329_bib40","first-page":"27","article-title":"Correlation of serum levels of interleukine-16, CCL27, tumor necrosis factor-related apoptosis-inducing ligand, and B-cell activating factor with multiple sclerosis severity","volume":"21","author":"Kouchaki","year":"2022","journal-title":"Iran. J. Allergy, Asthma Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib41","first-page":"285","article-title":"Novel opportunities for therapeutic targeting in systemic autoimmune diseases","volume":"361","author":"Ouarzane","year":"2007","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jaut.2024.103329_bib42","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/ni829","article-title":"DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL","volume":"3","author":"Litinskiy","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib43","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1084\/jem.20051283","article-title":"BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway","volume":"202","author":"Craxton","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2024.103329_bib44","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4049\/jimmunol.166.1.6","article-title":"Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus","volume":"166","author":"Zhang","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/sj.clpt.6100436","article-title":"Emerging biological therapies in systemic lupus erythematosus","volume":"83","author":"Mount","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jaut.2024.103329_bib46","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard-2022-223035","article-title":"Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study","volume":"82","author":"Tian","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103329_bib47","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.3390\/ijms20246231","article-title":"B cell abnormalities in systemic lupus erythematosus and lupus nephritis-role in pathogenesis and effect of immunosuppressive treatments","volume":"20","author":"Yap","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jaut.2024.103329_bib48","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/art.40396","article-title":"Abnormal B cell development in systemic lupus erythematosus: what the genetics tell us","volume":"70","author":"Karrar","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2024.103329_bib49","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.4049\/jimmunol.176.11.6405","article-title":"Space, selection, and surveillance: setting boundaries with BLyS","volume":"176","author":"Miller","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102736","article-title":"B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE)","volume":"20","author":"M\u00f6ckel","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2024.103329_bib51","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/intimm\/dxm011","article-title":"The role of BLyS\/BLyS receptors in anti-chromatin B cell regulation","volume":"19","author":"Hondowicz","year":"2007","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib52","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2003.018663","article-title":"Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus","volume":"63","author":"Stohl","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103329_bib53","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.reuma.2010.11.010","article-title":"[Interleukins network in rheumatoid arthritis pathophysiology: beyond proinflammatory cytokines]","volume":"6s3","author":"S\u00e1nchez-Ram\u00f3n","year":"2011","journal-title":"Reumatol. Cl\u00ednica"},{"key":"10.1016\/j.jaut.2024.103329_bib54","series-title":"AB0093 Blys and April Overexpression in Early Rheumatoid Arthritis: Association with B Cells and Myeloid Subsets","author":"Rodr\u00edguez-Carrio","year":"2017"},{"key":"10.1016\/j.jaut.2024.103329_bib55","doi-asserted-by":"crossref","first-page":"17050","DOI":"10.1002\/jcp.28445","article-title":"The role of BAFF and APRIL in rheumatoid arthritis","volume":"234","author":"Shabgah","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.jaut.2024.103329_bib56","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1517\/14728222.8.3.177","article-title":"Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders","volume":"8","author":"Stohl","year":"2004","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.jaut.2024.103329_bib57","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1074-7613(01)00183-2","article-title":"TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS","volume":"15","author":"Gross","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2024.103329_bib58","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/89782","article-title":"TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice","volume":"2","author":"Wang","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib59","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1172\/JCI25265","article-title":"BLyS and APRIL in rheumatoid arthritis","volume":"115","author":"Seyler","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2024.103329_bib60","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2215\/CJN.07420716","article-title":"IgA nephropathy","volume":"12","author":"Rodrigues","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jaut.2024.103329_bib61","series-title":"IgA Nephropathy (Berger Disease). StatPearls, Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2024","author":"Rawla","year":"2024"},{"key":"10.1016\/j.jaut.2024.103329_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002765","article-title":"Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis","volume":"8","author":"Kiryluk","year":"2012","journal-title":"PLoS Genet."},{"key":"10.1016\/j.jaut.2024.103329_bib63","article-title":"The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies","volume":"3","author":"Cheung","year":"2023","journal-title":"Front Nephrol"},{"key":"10.1016\/j.jaut.2024.103329_bib64","first-page":"795","article-title":"BAFF is involved in the pathogenesis of IgA nephropathy by activating the TRAF6\/NF-\u03baB signaling pathway in glomerular mesangial cells","volume":"21","author":"Cao","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jaut.2024.103329_bib65","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","article-title":"Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases","volume":"36","author":"Samy","year":"2017","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molimm.2020.11.010","article-title":"A novel BAFF antagonist, BAFF-Trap, effectively alleviates the disease progression of systemic lupus erythematosus in MRL\/lpr mice","volume":"129","author":"Yu","year":"2021","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib67","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.kint.2019.01.031","article-title":"A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy","volume":"96","author":"Myette","year":"2019","journal-title":"Kidney Int."},{"key":"10.1016\/j.jaut.2024.103329_bib68","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1681\/ASN.2015060677","article-title":"The role of TNF superfamily member 13 in the progression of IgA nephropathy","volume":"27","author":"Han","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jaut.2024.103329_bib69","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2024.103329_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109870","article-title":"B cell activating factor levels are linked to distinct B cell markers in multiple sclerosis and following B cell depletion and repopulation","volume":"258","author":"Asplund H\u00f6gelin","year":"2024","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib71","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrneurol.2012.203","article-title":"B cells and antibodies in multiple sclerosis pathogenesis and therapy","volume":"8","author":"Krumbholz","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jaut.2024.103329_bib72","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1172\/JCI26385","article-title":"Similarities and differences between selective and nonselective BAFF blockade in murine SLE","volume":"116","author":"Ramanujam","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2024.103329_bib73","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11926-012-0264-4","article-title":"Belimumab and the clinical data","volume":"14","author":"Shum","year":"2012","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.jaut.2024.103329_bib74","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/11538300-000000000-00000","volume":"10","author":"Benlysta","year":"2010","journal-title":"LymphoStat-B. Drugs R D"},{"key":"10.1016\/j.jaut.2024.103329_bib75","doi-asserted-by":"crossref","first-page":"568","DOI":"10.5604\/17322693.1007663","article-title":"[Biological therapies in systemic lupus erythematosus]","volume":"66","author":"Suszek","year":"2012","journal-title":"Postepy Hig. Med. Dosw."},{"key":"10.1016\/j.jaut.2024.103329_bib76","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/0961203312471575","article-title":"Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy","volume":"22","author":"Mosak","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2024.103329_bib77","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1586\/1744666X.2015.996550","article-title":"Belimumab for the treatment of systemic lupus erythematosus","volume":"11","author":"Jordan","year":"2015","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib78","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41467-018-03620-2","article-title":"BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus","volume":"9","author":"Shin","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2024.103329_bib79","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.3389\/fimmu.2018.02698","article-title":"Inhibition of membrane-bound BAFF by the anti-BAFF antibody belimumab","volume":"9","author":"Kowalczyk-Quintas","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib80","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.it.2011.06.004","article-title":"BAFF and selection of autoreactive B cells","volume":"32","author":"Liu","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib81","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1345\/aph.1P360","article-title":"Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus","volume":"44","author":"Wiglesworth","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jaut.2024.103329_bib82","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00105-012-2334-y","article-title":"[Belimumab. A new targeted therapeutic option for lupus erythematosus]","volume":"63","author":"Gl\u00e4ser","year":"2012","journal-title":"Hautarzt"},{"key":"10.1016\/j.jaut.2024.103329_bib83","doi-asserted-by":"crossref","DOI":"10.1186\/ar2506","article-title":"Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus","volume":"10","author":"Furie","year":"2008","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2024.103329_bib84","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/art.27189","article-title":"Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study","volume":"62","author":"Jacobi","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2024.103329_bib85","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103329_bib86","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1358\/dot.2010.46.12.1544336","article-title":"A BLyS-specific inhibitor for the treatment of systemic lupus erythematosus","volume":"46","author":"Espinosa","year":"2010","journal-title":"Drugs Today"},{"key":"10.1016\/j.jaut.2024.103329_bib87","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/1744666X.2017.1371592","article-title":"Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration","volume":"13","author":"Poh","year":"2017","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib88","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2024.103329_bib89","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/clpt.2011.290","article-title":"Belimumab: a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus","volume":"91","author":"Dennis","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jaut.2024.103329_bib90","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1177\/0961203318797425","article-title":"Belimumab restores Treg\/Th17 balance in patients with refractory systemic lupus erythematosus","volume":"27","author":"Prete","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2024.103329_bib91","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1177\/0961203313476154","article-title":"Belimumab for systemic lupus erythematosus: a practice-based view","volume":"22","author":"Parodis","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2024.103329_bib92","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1517\/17425255.2015.1077808","article-title":"Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus","volume":"11","author":"Jordan","year":"2015","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.jaut.2024.103329_bib93","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11926-012-0254-6","article-title":"Biologic differences between various inhibitors of the BLyS\/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?","volume":"14","author":"Stohl","year":"2012","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.jaut.2024.103329_bib94","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clim.2012.11.010","article-title":"Targeting the BLyS-APRIL signaling pathway in SLE","volume":"148","author":"La Cava","year":"2013","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib95","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1517\/14712598.2012.758248","article-title":"Belimumab--an anti-BLyS human monoclonal antibody for rheumatoid arthritis","volume":"13","author":"Jin","year":"2013","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.jaut.2024.103329_bib96","first-page":"311","article-title":"Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sj\u00f6gren's syndrome: follow-up after the end of the phase II open-label BELISS study","volume":"34","author":"Quartuccio","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2024.103329_bib97","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/ane.12915","article-title":"B cells in multiple sclerosis therapy-A comprehensive review","volume":"137","author":"Rahmanzadeh","year":"2018","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jaut.2024.103329_bib98","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1517\/14728222.2014.888415","article-title":"Therapeutic targeting of the BAFF\/APRIL axis in systemic lupus erythematosus","volume":"18","author":"Stohl","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.jaut.2024.103329_bib99","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/14712598.2016.1169270","article-title":"Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser","volume":"16","author":"Scheinberg","year":"2016","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.jaut.2024.103329_bib100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s13075-015-0741-z","article-title":"Treatment of systemic lupus erythematosus patients with the BAFF antagonist \"peptibody\" blisibimod (AMG 623\/A-623): results from randomized, double-blind phase 1a and phase 1b trials","volume":"17","author":"Stohl","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2024.103329_bib101","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2147\/DDDT.S114552","article-title":"Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date","volume":"11","author":"Lenert","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.jaut.2024.103329_bib102","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/annrheumdis-2013-205144","article-title":"A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study","volume":"74","author":"Furie","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103329_bib103","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/annrheumdis-2018-213032","article-title":"Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial","volume":"77","author":"Merrill","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103329_bib104","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/DDDT.S67264","article-title":"Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF\/APRIL targeting agents","volume":"9","author":"Lenert","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.jaut.2024.103329_bib105","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1007\/s10067-023-06781-8","article-title":"A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP)","volume":"42","author":"Williams","year":"2023","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2024.103329_bib106","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/art.37820","article-title":"Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial","volume":"65","author":"Genovese","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2024.103329_bib107","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1136\/annrheumdis-2013-203240","article-title":"eLetter: tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors by M Genovese","volume":"72","author":"Triantafyllou","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103329_bib108","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1136\/annrheumdis-2012-202775","article-title":"Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors","volume":"72","author":"Genovese","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103329_bib109","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/annrheumdis-2014-207090","article-title":"Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study","volume":"74","author":"Smolen","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103329_bib110","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1177\/0961203316650734","article-title":"The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials","volume":"25","author":"Rovin","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2024.103329_bib111","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/annrheumdis-2015-207653","article-title":"Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Isenberg","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103329_bib112","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","volume":"75","author":"Merrill","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103329_bib113","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.ekir.2022.01.1073","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of VIS649 (sibeprenlimab), an APRIL-neutralizing IgG(2) monoclonal antibody, in healthy volunteers","volume":"7","author":"Mathur","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jaut.2024.103329_bib114","doi-asserted-by":"crossref","first-page":"ii9","DOI":"10.1093\/ckj\/sfad200","article-title":"The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy","volume":"16","author":"Yeo","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.jaut.2024.103329_bib115","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaut.2018.10.016","article-title":"The role of APRIL - a proliferation inducing ligand - in autoimmune diseases and expectations from its targeting","volume":"95","author":"Baert","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2024.103329_bib116","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/ene.14105","article-title":"Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis","volume":"27","author":"Baker","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jaut.2024.103329_bib117","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1620\/tjem.2022.J074","article-title":"Telitacicept for recalcitrant cutaneous manifestations of systemic lupus erythematosus: a case report and review of the literature","volume":"258","author":"Ma","year":"2022","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.jaut.2024.103329_bib118","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1169084","article-title":"Telitacicept for autoimmune nephropathy","volume":"14","author":"Cai","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib119","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.jaut.2024.103329_bib120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1358\/dot.2022.58.1.3352743","article-title":"Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus","volume":"58","author":"Fan","year":"2022","journal-title":"Drugs Today"},{"key":"10.1016\/j.jaut.2024.103329_bib121","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"First approval","volume":"81","author":"Telitacicept","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jaut.2024.103329_bib122","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.intimp.2011.09.014","article-title":"TACI-Ig induces immune balance of Th cells in MLN via BLyS\/APRIL-receptors signaling in rats with adjuvant-induced arthritis","volume":"11","author":"Qin","year":"2011","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.jaut.2024.103329_bib123","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/cpdd.1136","article-title":"Pharmacokinetic characteristics, safety, and tolerability of telitacicept, an injectable recombinant human B-lymphocyte stimulating factor receptor-antibody fusion protein, in healthy Chinese subjects","volume":"11","author":"Xie","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jaut.2024.103329_bib124","first-page":"1267","article-title":"Advances in therapeutic targets-related study on systemic lupus erythematosus","volume":"46","author":"Wang","year":"2021","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"10.1016\/j.jaut.2024.103329_bib125","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/09612033221141253","article-title":"The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study","volume":"32","author":"Chen","year":"2023","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2024.103329_bib126","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/1744666X.2023.2145281","article-title":"B cell depletion and inhibition in systemic lupus erythematosus","volume":"19","author":"Krustev","year":"2023","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib127","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s40262-014-0175-9","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of single ascending doses of RCT-18 in Chinese patients with rheumatoid arthritis","volume":"53","author":"Chen","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jaut.2024.103329_bib128","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/cns.13904","article-title":"Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: a single-center, single-arm, open-label study","volume":"28","author":"Ding","year":"2022","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.jaut.2024.103329_bib129","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/14728214.2020.1803828","article-title":"Emerging drugs for the treatment of neuromyelitis optica","volume":"25","author":"Duchow","year":"2020","journal-title":"Expet Opin. Emerg. Drugs"},{"key":"10.1016\/j.jaut.2024.103329_bib130","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.596791","article-title":"Telitacicept following plasma exchange in the treatment of subjects with recurrent NMOSD: study protocol for a single-center, single-arm, open-label study","volume":"12","author":"Ding","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jaut.2024.103329_bib131","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40272-021-00457-z","article-title":"An update on the management of childhood-onset systemic lupus erythematosus","volume":"23","author":"Trindade","year":"2021","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jaut.2024.103329_bib132","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jaut.2024.103329_bib133","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/rheumatology\/kead265","article-title":"Efficacy and safety of telitacicept in primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"63","author":"Xu","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2024.103329_bib134","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/1756-185X.14752","article-title":"A patient with refractory proliferative lupus nephritis treated with telitacicept: a case report","volume":"26","author":"Chen","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jaut.2024.103329_bib135","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.cellimm.2014.03.017","article-title":"Combination of TACI-IgG and anti-IL-15 treats murine lupus by reducing mature and memory B cells","volume":"289","author":"Ma","year":"2014","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib136","first-page":"1331","article-title":"Profile of atacicept and its potential in the treatment of systemic lupus erythematosus","volume":"9","author":"Cogollo","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.jaut.2024.103329_bib137","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2024.103329_bib138","article-title":"Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme","volume":"3","author":"Gordon","year":"2019","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.jaut.2024.103329_bib139","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int."},{"key":"10.1016\/j.jaut.2024.103329_bib140","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/art.42462","article-title":"Povetacicept, an enhanced dual APRIL\/BAFF antagonist that modulates B lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B cell-related autoimmune diseases","volume":"75","author":"Evans","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2024.103329_bib141","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/17425247.2018.1517746","article-title":"Delivery approaches for CRISPR\/Cas9 therapeutics in vivo: advances and challenges","volume":"15","author":"Luther","year":"2018","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.jaut.2024.103329_bib142","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nature.2016.20988","article-title":"CRISPR gene-editing tested in a person for the first time","volume":"539","author":"Cyranoski","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2024.103329_bib143","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-1-4939-7095-7_12","article-title":"CRISPR\/Cas9-Mediated in vitro mutagenesis in GC-like B cells","volume":"1623","author":"Chu","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jaut.2024.103329_bib144","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3389\/fonc.2020.00682","article-title":"The role of BAFF-R signaling in the growth of primary central nervous system lymphoma","volume":"10","author":"Zhou","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jaut.2024.103329_bib145","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s11481-012-9384-x","article-title":"Antibodies against human BLyS and APRIL attenuate EAE development in marmoset monkeys","volume":"7","author":"Jagessar","year":"2012","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.jaut.2024.103329_bib146","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/intimm\/dxl080","article-title":"A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses","volume":"18","author":"Huntington","year":"2006","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib147","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1172\/JCI0214121","article-title":"Association of BAFF\/BLyS overexpression and altered B cell differentiation with Sj\u00f6gren's syndrome","volume":"109","author":"Groom","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2024.103329_bib148","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1586\/1744666X.2013.816479","article-title":"B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress","volume":"9","author":"Md Yusof","year":"2013","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib149","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s10875-012-9709-9","article-title":"Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse","volume":"32","author":"Wang","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.jaut.2024.103329_bib150","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","article-title":"A review in systemic lupus erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jaut.2024.103329_bib151","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bcp.12860","article-title":"Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus","volume":"81","author":"Witcher","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jaut.2024.103329_bib152","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1177\/09612033221097812","article-title":"Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: a self-controlled before-after trial","volume":"31","author":"Sun","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2024.103329_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105704","article-title":"Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS\/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis","volume":"159","author":"Yao","year":"2021","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.jaut.2024.103329_bib154","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/kjm2.12719","article-title":"Telitacicept for minimal change disease","volume":"39","author":"Li","year":"2023","journal-title":"Kaohsiung J. Med. Sci."},{"key":"10.1016\/j.jaut.2024.103329_bib155","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/1756-185X.14613","article-title":"Safety, efficacy and pharmacokinetics of low-dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus","volume":"26","author":"Guan","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jaut.2024.103329_bib156","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1136\/ard-2022-223529","article-title":"BLyS\/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept","volume":"82","author":"Cai","year":"2023","journal-title":"Ann. Rheum. Dis."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089684112400163X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089684112400163X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T11:41:55Z","timestamp":1738496515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089684112400163X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":156,"alternative-id":["S089684112400163X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103329","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The emerging role of BLyS\/APRIL in autoimmune diseases: Biological characteristics, functions, and therapeutic potential","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103329","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103329"}}